BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Treatment
147 results:

  • 1. Association of the Advanced Lung cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
    Jiang H; Li B; Wu M; Wang Q; Li Y
    BMC Cancer; 2024 Apr; 24(1):428. PubMed ID: 38589844
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study.
    Boyd S; Mustamäki T; Sjöblom N; Nordin A; Tenca A; Jokelainen K; Rantapero T; Liuksiala T; Lahtinen L; Kuopio T; Kytölä S; Mäkisalo H; Färkkilä M; Arola J
    Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38551383
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP.
    Zhan Z; Guo W; Wan X; Wang B; Li J; Wang H; Li Z; Huang Y; Young KH; Bai O
    Front Immunol; 2024; 15():1324113. PubMed ID: 38318173
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Anatomical thermal ablation as an alternative to surgical resection for subcapsular hepatocellular carcinoma.
    Long Y; Zeng Q; He X; Wu Y; Ye H; Xu J; Chen J; Yuan L; Li H; Li K
    Abdom Radiol (NY); 2024 Apr; 49(4):1144-1153. PubMed ID: 38289353
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
    Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A real-world data analysis-based study of Chinese medicine treatment patterns after breast cancer surgery.
    Hu L; Yang Y; Wang Z; Wen C; Cheng X
    Medicine (Baltimore); 2023 Dec; 102(50):e36642. PubMed ID: 38115283
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination.
    Cao K; Wang R; Li L; Liao Y; Hu X; Li R; Liu X; Xiong XD; Wang Y; Liu X
    Oncogene; 2024 Jan; 43(1):35-46. PubMed ID: 38007537
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.
    Němčíková P; Brunerová L
    Vnitr Lek; 2023; 69(5):312-315. PubMed ID: 37827829
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Hepatitis B virus infection disrupts homologous recombination in hepatocellular carcinoma by stabilizing resection inhibitor ADRM1.
    Zeng M; Tang Z; Ren L; Wang H; Wang X; Zhu W; Mao X; Li Z; Mo X; Chen J; Han J; Kong D; Ji J; Carr AM; Liu C
    J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 37815873
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A novel prognostic model based on AFP, tumor burden score and Albumin-Bilirubin grade for patients with hepatocellular carcinoma undergoing radiofrequency ablation.
    Huang J; Cui W; Xie X; Lin K; Jin D; Xie X; Zhuang B
    Int J Hyperthermia; 2023; 40(1):2256498. PubMed ID: 37733400
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genomic profile of Pancoast syndrome due to hepatocellular carcinoma: A case report.
    Bergman DT; Zaki L; Pettus JR; Zaki BI; Amin M
    Thorac Cancer; 2023 Jun; 14(18):1789-1792. PubMed ID: 37160416
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.
    Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
    Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The deubiquitinating enzyme UCHL3 promotes anaplastic thyroid cancer progression and metastasis through Hippo signaling pathway.
    Tang J; Yang Q; Mao C; Xiao D; Liu S; Xiao L; Zhou L; Wu G; Tao Y
    Cell Death Differ; 2023 May; 30(5):1247-1259. PubMed ID: 36813921
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Treatment and Prognosis of Fibrolamellar Hepatocellular Carcinoma: a Systematic Review of the Recent Literature and Meta-analysis.
    Glavas D; Bao QR; Scarpa M; Ruffolo C; Brown ZJ; Pawlik TM; Spolverato G
    J Gastrointest Surg; 2023 Apr; 27(4):705-715. PubMed ID: 36797535
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Bevacizumab and atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial.
    Lee YC; Huang WT; Lee MY; Tsao CJ; Feng YH
    In Vivo; 2023; 37(1):454-460. PubMed ID: 36593061
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy.
    Yuan B; Ma J; Wang J; Hao J
    Front Endocrinol (Lausanne); 2022; 13():1060768. PubMed ID: 36583006
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Eur J Intern Med; 2023 Jan; 107():66-72. PubMed ID: 36347739
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma.
    Nicolosi A; Gaia S; Risso A; Rosso C; Rolle E; Abate ML; Olivero A; Armandi A; Ribaldone DG; Carucci P; Fagoonee S; Pellicano R; Saracco GM; Bugianesi E; Caviglia GP
    Minerva Gastroenterol (Torino); 2022 Dec; 68(4):378-386. PubMed ID: 36222678
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. BI6727, a polo-like kinase 1 inhibitor, synergizes with gefitinib to suppress hepatocellular carcinoma cells via a G2/M arrest mechanism.
    Zhou Q; Chen T
    Pharmazie; 2022 Sep; 77(7):230-235. PubMed ID: 36199185
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 8.